1.Suerbaum S, Michetti P. Helicobacter Pylori infection. N Engl J Med 2002;3:1175–1186.
2.Tamer GS, Tengiz I, Ercan E, et al. Helicobacter pylori seropositivity in patients with acute coronary syndromes. Dig Dis Sci 2009;54:1253–1256.
3.Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996;41:458–461.
4.Laurila A, Bloigu A, Näyhä S, et al. Association of Helicbacter pylori infection with elevated serum lipids. Atherosclerosis. 1999;142:207–210.
5.Hoffmeister A, Rothenbacher D, Bode G, et al. Current infection with Helicobacter pylori but not seropositivity to Chlamydia pneumoniae or Cytamegalovirus is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001;21:427–432.
6.Jha HC, Prasad J, Mittal A. High immunoglobulin A seropositivity for combined Chlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker. Heart Vessels 2008;23:390–396.
7.Stettin D, Waldmann A, Ströhle A, et al. Association between Helicobacter pylori infection, C-reactive protein and status of B vitamis. Adv Med Sci 2008;53:205–213.
8.Hedblad B, Nilsson P, Engström G, et al. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002;19:470–475.
9.Eshraghian A, Hashemi SA, Hamidian Jahromi A, et al. Helicobacter pylori Infection as a risk factor for insulin resistance. Dig Dis Sci 2009;54:1966–1970.
10.Ozdem S, Akcam M, Yilmaz A, et al. Insulin resistance in children with Helicobacter pylori infection. J Endocrinol Invest 2007;30:236–240.
11.Gunji T, Matsuhashi N, Sato H, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008;105:3005–3010.
12.Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007;121:229–238.
13.Park SH, Jeon WK, Kim SH, et al. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc 2005;97:508–513.
14.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
15.Kadayifci A, Buyukhatipoglu H, Cemil Savas M, et al. Eradication of Helicobacter pylori with triple therapy:an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006;28:1960–1966.
16.Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
17.Tong JL, Ran ZH, Shen J, et al. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41–53.
18.Sezgin O, Altintaş E, Nayir E, et al. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter 2007;12:629–632.
19.Perri F, Villani MR, Festa V, et al. Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy.’ Aliment Pharmacol Ther 2001;15:1023–1029.
20.Sezgin O, Aslan G, Altintaş E, et al. Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey. Turk J Gastroenterol 2008;19:163–167.
21.Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degree of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.
22.Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959–965.
23.Kaneko H, Konagaya T, Kusugami K. Helicobacter pylori and gut hormones. J Gastroenterol 2002;37:77–86.
24.Silha JV, Nyomba BL, Leslie WD, et al. Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care 2007;30:286–291.
25.Festa A, D'Agostina R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999;19:562–568.
26.Genta RM. The immunobiology of Helicobacter pylori gastritis. Semin Gastrointest Dis 1997;8:2–11.
27.Lankarani KB, Moghadami M, Masoumpoor M, et al. Serum leptin level in patients with functional dyspepsia. Dig Liver Dis 2004;36:717–721.
28.Hennige AM, Stefan N, Kapp K, et al. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 2006;20:1206–1208.
29.Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–660.
30.Pöykkö SM, Kellokoski E, Hörkkö S, et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003;52:2546–2553.
31.Shiotani A, Miyanishi T, Uedo N, et al. Helicobacter pylori infection is associated with reduced circulating ghrelin levels independent of body mass index. Helicobacter 2005;10:373–378.
32.Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998;316:1130–1132.
33.Kucukazman M, Yavuz B, Sacikara M, et al. The relationship between updated Sydney System score and LDL cholesterol levels in patients infected with Helicobacter pylori. Dig Dis Sci 2009;5:604–607.
34.Kanbay M, Gür G, Yücel M, et al. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 2005;50:1228–1231.
35.Fischer W, Prassl S, Haas R. Virulence mechanisms and persistence strategies of the human gastric pathogen Helicobacter pylori. Curr Top Microbiol Immunol 2009;337:129–171.
36.Caruso R, Fina D, Paoluzi OA, et al. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol 2008;38:470–478.
37.Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc 2004;96:1470–1476.